GFAP R416WT Antibody, Clone N206B/9: ATTO 594

Mouse Anti-Human GFAP R416WT Monoclonal IgG1

Product Specifications

Background

Glial fibrillary acidic protein (GFAP) is a 50 kDa type III intermediate filament protein that serves as a key structural component of astrocytes in the central nervous system. It plays a critical role in maintaining astrocyte architecture and function. GFAP polymerization is regulated through phosphorylation and interactions with calcium-binding proteins such as annexin II-p2 and S-100, enabling dynamic responses to physiological and pathological stimuli. One of the earliest and most prominent astrocytic responses to central nervous system injury is astrogliosis, characterized by astrocyte proliferation and hypertrophy. A hallmark of this process is the upregulation of GFAP expression, making it a widely used biomarker for reactive astrocytes and neuroinflammation. In the context of neurodegenerative diseases—including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis—elevated GFAP levels reflect ongoing glial activation and are associated with disease progression. Notably, autoantibodies against GFAP have been detected in individuals with dementia, suggesting a potential link between astrocytic dysfunction and neuroimmune mechanisms in neurodegeneration. Due to its specificity and responsiveness to neural injury, GFAP is extensively used in both experimental and clinical neuroscience as a diagnostic and prognostic marker. Its role in glial biology and neuroinflammation continues to make it a focal point in the development of therapeutic strategies targeting astrocyte-mediated pathology.

CAS Number

9007-83-4

Specifications

Detects ~50kDa. Does not cross-react with GFAP-R416W or other proteins (based on KO validation results).

Product Name Alternative

GFAP, Glial fibrillary acidic protein, Intermediate filament protein, Astrocyte, GFAPL, DKFZp459C0729, MGC139638, FLJ45472, AI836096

Synonyms

GFAP R416WT Antibody, Clone N206B/9: ATTO 594

UNSPSC

12352203

UN Code

Non-hazardous

Hazard Statement

Non-hazardous

Gene ID

2670

Swiss Prot

P14136

Accession Number

NP_001124491.1

Cellular Locus

Cytoplasm

Host

Mouse

Species Reactivity

Human,Mouse,Rat

Immunogen

Synthetic peptide amino acids 411-422 (KTVEMRDGEVIK) of human GFAP; 100% identical in rat and mouse. >50% identity with other proteins (Vimentin, Desmin and Peripherin) .

Target

GFAP

Clonality

Monoclonal

Isotype

IgG1

Clone

N206B/9 (Formerly sold as S206B-9)

Conjugation

ATTO 594

Type

Monoclonal

Applications

WB | IHC | ICC/IF

Validated Applications

IHC,ICC/IF

Field of Research

Neuroscience | Cell Markers | Glial Markers | Astrocyte Markers

Purification

Protein G Purified

Limit Of Detection

1 µg/ml of SMC-442 was sufficient for detection of GFAP R416WT in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.

Concentration

1 mg/ml

Dilution

WB (1:1000) ; optimal dilutions for assays should be determined by the user.

Weight

0.1

Buffer

640.91mM DMSO, 136.36 mM Ethanolamine, 126.89 mM chlorides, 9.09mM phosphates, 9.09mM NaHCO3

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

References & Citations

1. Velasco M.E., et al. (1980) Cancer. 45:484. 2. Bonnin J.M., et al. (1984) Acta Neuropathology. 62:185. 3. Lee VM-Y., et al. (1984) J. Neurochem. 42:25-32 (1984). 4. Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986). 5. Schmidt ML et al; Lab Invest 56:282-294 (1987). 6. Kosik KS et al; Neuron 1:817-825 (1988). 7. Schmidt ML et al; Lab Invest 59:460-466 (1988). 8. Mokuna, K, et al: J Neurosci Res 23:396 (1989). 9. Molenaar, et al; Exp Neurology 108:1-9 (1990). 10. Tohyama T et al; Am J Pathol, 142:871-882 (1993). 11. Tohyama T et al; Am J Pathol 142:883-892 (1993). 12. Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).

Shipping Conditions

Blue Ice or 4ºC

Storage Conditions

Conjugated antibodies should be stored according to the product label

Specificity

Detects ~50kDa. Does not cross-react with GFAP-R416W or other proteins (based on KO validation results) .

Background Reference 01

1. Velasco M.E., et al. (1980) Cancer. 45:484. 2. Bonnin J.M., et al. (1984) Acta Neuropathology. 62:185. 3. Lee VM-Y., et al. (1984) J. Neurochem. 42:25-32 (1984) . 4. Trojanowski JQ et al. (1986) J. Neurochem. 6 (3) : 650-660 (1986) . 5. Schmidt ML et al; Lab Invest 56:282-294 (1987) . 6. Kosik KS et al; Neuron 1:817-825 (1988) . 7. Schmidt ML et al; Lab Invest 59:460-466 (1988) . 8. Mokuna, K, et al: J Neurosci Res 23:396 (1989) . 9. Molenaar, et al; Exp Neurology 108:1-9 (1990) . 10. Tohyama T et al; Am J Pathol, 142:871-882 (1993) . 11. Tohyama T et al; Am J Pathol 142:883-892 (1993) . 12. Thilenius, A.R.B., et al; J. Immunol. 162 (2) : 643-650 (1999) .